Table 1 Cohort characteristics
Studies | Cases | Mean age | Female patient | Surgical methods | TXA intervention | Prophylactic antithrombotic | Transfusion trigger follow-up | |
|---|---|---|---|---|---|---|---|---|
(E/C) | (E/C) | (E/C) | ||||||
Huang 2014 [7] | 92/92 | 65.4/64.7 | 55/62 | TKA | E:1.5 g topical injection +1.5 g i.v. | LMWH, 6000 IU | HB less than 7 g/dL | 1–3 months |
C:3 g i.v. | ||||||||
Nielsen 2016 [8] | 30/30 | 65.5/63.2 | 17/15 | TKA | E:3 g topical injection + 1 g i.v. | Rivaroxaban, 10 mg | HB less than 7.5 g/dL | 3 months |
C:3 g i.v. | ||||||||
Jain 2016 [12] | 59/60 | 68.3/70.0 | 39/36 | TKA | E:pre-op.15 mg/kg i.v. + post-op.10 mg/kg i.v. + 2 g topical injection | Aspirin, 75 mg | HB less than 7 g/dL | NS |
C:pre-op.15 mg/kg i.v. + post-op.10 mg/kg i.v | ||||||||
Xie 2016 [11] | 70/70 | 60.5/59.5 | 48/50 | THA | E:1 g topical injection + 2 g i.v. | Enoxaparin, 6000 IU | HB less than 7 g/dL | 1–3 months |
C:1.5 g i.v. | ||||||||
Wu 2016 [10] | 42/42 | 60.1/59.5 | 19/21 | Reversion THA | E:3 g topical injection +15 mg/kg i.v. | LMWH, 6000 IU | HB less than 8 g/dL | 3 months |
C:15 mg/kg i.v. | ||||||||
Song 2016 [9] | 50/50 | 70.8/69.2 | 43/44 | TKA | E: 1.5 g topical injection +10 mg/kg i.v. C:E:pre-op.10 mg/kg i.v. + post-op.10 mg/kg | Not performed | HB less than 8 g/dL | 1 month |